Department of Neurological Surgery, University of California, San Francisco, California 94117, USA.
J Neurosurg. 2010 Jan;112(1):26-32. doi: 10.3171/2009.3.JNS081081.
Although secondary gliosarcoma after treatment of primary glioblastoma multiforme has been described, little is known of these rare tumors. In this article the authors review the literature on secondary gliosarcoma, with attention to clinical course and pathological features.
A PubMed search of the key word intracranial "gliosarcoma" with and without "radiation" or "radiotherapy" in humans was performed. The 204 citations yielded were screened for relevancy to gliosarcomas that occur after treatment of previous intracranial neoplasms.
A search of the literature yielded 24 relevant articles, combined for a total of only 12 cases of secondary gliosarcoma and 12 cases of radiation-induced gliosarcoma. Of the 12 cases of secondary gliosarcoma, all were previously treated with surgery and radiotherapy (mean dose 50.7 Gy), with a mean survival of 13 months since time of gliosarcoma diagnosis (range 6.9-19.4 months). In the cases of radiation-induced gliosarcoma, the mean dose of previous radiotherapy was 51.3 Gy (median 54 Gy, range 24-60 Gy), and the mean survival since gliosarcoma diagnosis was 6.7 months (median 6 months, range 2-10 months).
Secondary gliosarcoma and radiation-induced gliosarcoma are exceedingly rare. The literature on secondary gliosarcoma illustrates a more favorable survival than for primary gliosarcoma but remains limited regarding clinical and radiographic presentation, response to treatment, and pathogenesis. The results of the present review also support the notion that secondary gliosarcomas and radiation-induced gliosarcomas are distinct entities, with longer survival and shorter latency of gliosarcoma induction seen in the former. Efforts to elucidate the role of radiotherapy in the induction of gliosarcomas may yield new insights into therapeutic risks of cranial radiation and CNS tumor pathogenesis.
尽管已经描述了治疗多形性胶质母细胞瘤后的继发性神经胶质瘤肉瘤,但对这些罕见肿瘤知之甚少。本文作者回顾了继发性神经胶质瘤肉瘤的文献,重点关注其临床病程和病理特征。
在 PubMed 上使用“颅内神经胶质瘤肉瘤”和“放疗”或“放射疗法”作为关键词进行检索,对 204 篇参考文献进行筛选,以确定与先前颅内肿瘤治疗后发生的神经胶质瘤肉瘤相关的文献。
文献检索共获得 24 篇相关文章,其中仅汇总了 12 例继发性神经胶质瘤肉瘤和 12 例放疗诱导性神经胶质瘤肉瘤。在 12 例继发性神经胶质瘤肉瘤中,所有患者均接受过手术和放疗(平均剂量 50.7Gy),自诊断为神经胶质瘤肉瘤以来的平均生存时间为 13 个月(6.9-19.4 个月)。在放疗诱导性神经胶质瘤肉瘤中,先前放疗的平均剂量为 51.3Gy(中位数 54Gy,范围 24-60Gy),自诊断为神经胶质瘤肉瘤以来的平均生存时间为 6.7 个月(中位数 6 个月,范围 2-10 个月)。
继发性神经胶质瘤肉瘤和放疗诱导性神经胶质瘤肉瘤极为罕见。继发性神经胶质瘤肉瘤的文献表明,其生存率优于原发性神经胶质瘤肉瘤,但在临床表现、治疗反应和发病机制方面的资料仍然有限。本研究的结果还支持这样一种观点,即继发性神经胶质瘤肉瘤和放疗诱导性神经胶质瘤肉瘤是不同的实体肿瘤,前者的神经胶质瘤肉瘤诱导潜伏期更短,生存时间更长。阐明放疗在诱导神经胶质瘤肉瘤中的作用,可能有助于深入了解颅部放疗的治疗风险和中枢神经系统肿瘤的发病机制。